Display of DNA on Nanoparticles for Targeting Antigen Presenting Cells
Source abstract
Abstract
Efficient delivery of antigens is of paramount concern in immunotherapies. We aimed to target antigen presenting cells (APCs) by conjugating CpG oligonucleotides to an E2 protein nanoparticle surface (CpG-PEG-E2). Compared to E2 alone, we observed ∼4-fold increase of in vitro APC uptake of both CpG-PEG-E2 and E2 conjugated to non-CpG DNA. Furthermore, compared to E2-alone or E2 functionalized solely with polyethylene glycol (PEG), the CpG-PEG-E2 showed enhanced lymph node retention up to at least 48 h and 2-fold increase in APC uptake in vivo, parameters which are advantageous for vaccine success. This suggests that enhanced APC uptake of nanoparticles mediated by oligonucleotide display may help overcome delivery barriers in vaccine development.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · T-cell and B-cell Immunology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering and Materials Science, §Department of Medicine, ⊥Chao Family Comprehensive Cancer Center, ∥Institute for Immunology, and #Department of Biomedical Engineering, University of California, Irvine, California 92697, United States
Funding
National Cancer Institute · National Institute of Biomedical Imaging and Bioengineering · Cancer Research Coordinating Committee, University of California
References (40)
Show source-provided references
1. 10.1016/j.jim.2012.05.01410.1016/j.jim.2012.05.014 ↗
2. 10.1126/scitranslmed.aaf068510.1126/scitranslmed.aaf0685 ↗
3. 10.1038/nri286810.1038/nri2868 ↗
4. 10.1038/nrc325810.1038/nrc3258 ↗
5. 10.1177/153537021664712310.1177/1535370216647123 ↗
6. 10.1038/nrc.2015.310.1038/nrc.2015.3 ↗
7. 10.1021/bc050217o10.1021/bc050217o ↗
8. 10.1016/j.biomaterials.2011.04.08210.1016/j.biomaterials.2011.04.082 ↗
9. 10.1016/j.smim.2011.01.00410.1016/j.smim.2011.01.004 ↗
10. 10.1073/pnas.120879610910.1073/pnas.1208796109 ↗
11. 10.1002/bit.2198810.1002/bit.21988 ↗
12. 10.1021/nn403085w10.1021/nn403085w ↗
13. 10.1021/bm300083e10.1021/bm300083e ↗
14. 10.1016/j.biomaterials.2016.01.05610.1016/j.biomaterials.2016.01.056 ↗
15. 10.1002/smll.20100224210.1002/smll.201002242 ↗
16. 10.1016/j.bej.2013.09.00810.1016/j.bej.2013.09.008 ↗
17. 10.1016/j.copbio.2013.12.00710.1016/j.copbio.2013.12.007 ↗
18. 10.1002/wnan.11910.1002/wnan.119 ↗
19. 10.1021/acsbiomaterials.5b0034410.1021/acsbiomaterials.5b00344 ↗
20. 10.1046/j.1365-2249.2003.02107.x10.1046/j.1365-2249.2003.02107.x ↗
21. 10.3892/ijo_0000052810.3892/ijo_00000528 ↗
22. 10.4049/jimmunol.165.12.688910.4049/jimmunol.165.12.6889 ↗
23. 10.1158/1078-0432.CCR-04-002210.1158/1078-0432.CCR-04-0022 ↗
24. 10.1021/acs.bioconjchem.6b0010710.1021/acs.bioconjchem.6b00107 ↗
25. 10.2217/nnm.11.1910.2217/nnm.11.19 ↗
26. 10.1021/bm801274210.1021/bm8012742 ↗
27. 10.1021/bc100242310.1021/bc1002423 ↗
28. 10.1111/j.1462-5822.2009.01326.x10.1111/j.1462-5822.2009.01326.x ↗
29. 10.1126/science.109915310.1126/science.1099153 ↗
30. 10.1016/j.biomaterials.2011.01.02110.1016/j.biomaterials.2011.01.021 ↗
31. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
32. 10.3390/vaccines302039010.3390/vaccines3020390 ↗
33. 10.1615/CritRevTherDrugCarrierSyst.v25.i5.1010.1615/CritRevTherDrugCarrierSyst.v25.i5.10 ↗
34. 10.1007/978-1-60327-248-3_910.1007/978-1-60327-248-3_9 ↗
35. 10.1038/gt.2009.9510.1038/gt.2009.95 ↗
36. 10.1038/nature1297810.1038/nature12978 ↗
37. 10.4049/jimmunol.140062310.4049/jimmunol.1400623 ↗
38. 10.1371/journal.ppat.100305410.1371/journal.ppat.1003054 ↗
39. 10.1371/journal.pone.006164610.1371/journal.pone.0061646 ↗
40. 10.1002/eji.20073798410.1002/eji.200737984 ↗